key: cord-0701300-waupx5k7
authors: Cucunawangsih, Cucunawangsih; Wijaya, Ratna Sari; Lugito, Nata Pratama Hardjo; Suriapranata, Ivet
title: Post-vaccination COVID-19 cases among healthcare workers at Siloam Teaching Hospital, Indonesia
date: 2021-05-13
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.05.020
sha: ca1a841539bedc1c2468af9a8ae546eba0f581c1
doc_id: 701300
cord_uid: waupx5k7

Background Healthcare workers (HCWs) compared to the general population are at an increased risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease-19 (COVID-19). Therefore, they are given priority for the COVID-19 vaccine in the national COVID-19 vaccination campaign in Indonesia. However, when the daily new COVID-19 cases are still high, and the data regarding the vaccine’s efficacy in healthcare settings remains unavailable, the vaccinated HCWs still likely to get COVID-19 infection and at risk for further transmission. Objective To identify COVID-19 cases among vaccinated HCWs at Siloam Teaching Hospital, Indonesia, via active and passive surveillance conducted by the hospital’s COVID-19 infection prevention and control unit Results Among 1,040 HCWs who have received the first and second vaccination, 13 (1.25%) HCWs were positive for SARS-CoV-2 RNA detection by reverse-transcriptase polymerase chain reaction (RT-PCR) from 2-11 days (median five days) after the second vaccination. Conclusion The early laboratory-confirmed COVID-19 among post-vaccinated HCWs indicates that HCWs are still at risk to acquire COVID-19 disease during the vaccination campaign. Therefore, the presence of symptoms after vaccination cannot be considered as vaccine-related symptoms, and regular COVID-19 testing should be conducted among HCWs.

Among the 13 HCWs who tested positive for COVID-19, 11 were tested because they had influenza-like illness symptoms, such as fever, cough, headache, chills, sore throat, and myalgia. Two asymptomatic COVID-19 HCWs were identified as a part of post-exposure screening. The median time between the second vaccination and the onset of symptoms was three days (range 0-10 days). None of the HCWs with COVID-19 disease in this study required hospitalization. Recent studies have indicated the people aged over 60-year with preexisting comorbidities were more likely to have unfavourable clinical outcome of COVID-19

disease (Bonanad et al., 2020; Luo et al., 2020) . Previous report has shown that the distribution of angiotensin-converting enzyme (ACE)-2, an entry receptor of SARS-CoV-2, was mainly detected in older patients' lower pulmonary tract. Additionally, the lung progenitor cells that play an important role in the lung repair process were found in lower frequency, potentially contributing to the poor prognosis of COVID-19 disease in older patients (Z. . However, in our study, all HCWs are under the age of 60, which is potentially the main factor determining the favourable clinical outcome of COVID-19 disease among HCWs.

The median time between the onset of symptoms and positive RT-PCR testing was five days (range 2-11 days). The gene targets for RT-PCR assay were the N gene and ORF1ab gene. there is a positive correlation between these two antibodies (Burbelo et al., 2020; McAndrews et al., 2020; To et al., 2020) . Although there was no available data regarding N-specific antibody titer or the efficacy of CoronaVac after the first vaccination, early studies had reported the antibody levels against SARS-CoV-2 antigen did not significantly increase until 14 days after the second dose of vaccination (Xia et al., 2020; Y. Zhang et al., 2021) . Thus, it J o u r n a l P r e -p r o o f indicates the HCWs still at risk of acquiring COVID-19 in the initial phase after completing two doses of COVID-19 vaccination.

In conclusion, vaccinated HCWs remains at risk to acquire SARS-CoV-2 infection, especially in Indonesia, where the frequency of COVID-19 cases is still high. Therefore, any COVID-19 symptoms found among vaccinated HCWs should not be considered as a vaccinerelated systemic event. Hence, they must be suspected as COVID-19 cases until the COVID-19 infection can be ruled out from diagnosis. Furthermore, active and passive surveillance and routine laboratory testing are essential to identify COVID-19 among HCWs and prevent secondary SARS-CoV-2 transmission to patients, other HCWs, and throughout healthcare settings. These measurements have to be strictly implemented until the systematic and comprehensive data regarding the CoronaVac effectiveness in healthcare settings are available.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

The effect of age on mortality in patients with covid-19: A meta-analysis with 611,583 subjects

Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019

Viral targets for vaccines against covid-19

Situasi terkini perkembangan coronavirus diseases (covid-19) 2021. Retrieved Feburary 28

Age differences in clinical features and outcomes in patients with covid-19, jiangsu, china: A retrospective, multicentre cohort study

Heterogeneous antibodies against sars-cov-2 spike receptor binding domain and nucleocapsid with implications for covid-19 immunity

Sars-cov-2 virus culture and subgenomic rna for respiratory specimens from patients with mild coronavirus disease

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by sars-cov-2: An observational cohort study

Update on coronavirus disease in indonesia

Effect of an inactivated vaccine against sars-cov-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials

Safety, tolerability, and immunogenicity of an inactivated sars-cov-2 vaccine in healthy adults aged 18-59 years: A randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial

Distinct disease severity between children and older adults with covid-19: Impacts of ace2 expression, distribution, and lung progenitor cells

Designing research studies (CC, RW, NL), acquiring data (CC), analyzing data (CC, RW, NL, IS), interpreting the results (CC, RW, NL, IS), and writing the manuscript (CC, RW, NL, IS).